International Aids Vaccine Initiative

🇰🇪Kenya

Country: 🇰🇪Kenya

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: -

Website: http://www.iavi.org

Clinical Trials

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
Biological: Placebo

First Posted Date: 2020-01-13

Last Posted Date: 2024-12-05

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 48

Registration Number: NCT04224701

Locations: 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
Rockefeller University, New York, New York, United States
🇳🇱
The Amsterdam University Medical Centers, Amsterdam, Netherlands

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Phase 1

Active, not recruiting

Conditions: HIV-1-infection

Interventions: Biological: 10-1074-LS-J
Biological: 3BNC117-LS-J
Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1
Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3
Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Biological: Combination 3BNC117-LS-J and 10-1074-LS-J
Biological: Placebo

First Posted Date: 2019-11-22

Last Posted Date: 2023-03-10

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 225

Registration Number: NCT04173819

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇿🇦
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 6 locations

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Biological: PGT121 + VRC07-523LS + PGDM1400
Biological: PGT121 + VRC07-523LS

First Posted Date: 2018-10-26

Last Posted Date: 2022-05-10

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 19

Registration Number: NCT03721510

Locations: 🇺🇸
Center for Virology and Vaccine Research/ Clinical Trials Unit/ BIDMC, Boston, Massachusetts, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Houston AIDS Research Team (HART), Houston, Texas, United States

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: BG505 SOSIP.664 gp140, adjuvanted
Biological: Placebo

First Posted Date: 2018-10-09

Last Posted Date: 2023-12-14

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 61

Registration Number: NCT03699241

Locations: 🇰🇪
Kenya AIDS Vaccine Initiative, Nairobi, Kenya
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
MGH, Boston, Massachusetts, United States

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Biological: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
Biological: DPBS Sucrose

First Posted Date: 2018-06-06

Last Posted Date: 2022-05-12

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 46

Registration Number: NCT03547245

Locations: 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Phase 2

Active, not recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Biological: Placebo

First Posted Date: 2018-04-30

Last Posted Date: 2024-02-22

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 831

Registration Number: NCT03512249

Locations: 🇿🇦
South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester, Cape Town, Western Cape, South Africa
🇿🇦
Task Clinical Research Centre, Bellville, Cape Town, South Africa
🇿🇦
University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa

and more 3 locations

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: PGDM1400/Placebo (10mg/kg IV)
Biological: PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)
Biological: PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)
Biological: PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)
Biological: PGDM1400 + PGT121 (MTD IV)
Biological: PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)
Biological: PGDM1400/Placebo (3mg/kg IV)
Biological: PGDM1400/Placebo (30mg/kg IV)

First Posted Date: 2017-07-02

Last Posted Date: 2020-09-14

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 29

Registration Number: NCT03205917

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

Phase 1

Completed

Conditions: HIV Infection

Interventions: Biological: PGT121 10mg/kg IV
Biological: PGT121 30mg/kg IV
Biological: PGT121 3mg/kg SC
Biological: PGT121 3mg/kg IV
Biological: Placebo (0.9% Sodium Chloride Injection USP (Saline))

First Posted Date: 2016-11-09

Last Posted Date: 2019-09-17

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 48

Registration Number: NCT02960581

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: MTBVAC
Biological: BCG

First Posted Date: 2016-10-14

Last Posted Date: 2023-02-27

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 144

Registration Number: NCT02933281

Locations: 🇿🇦
SATVI: Worcester, Worcester, South Africa

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

Phase 1

Completed

Conditions: HIV

Interventions: Biological: rcAd26.MOS1.HIV-Env 1x10^9 vp
Biological: rcAd26.MOS1.HIV-Env 1x10^10 vp
Biological: rcAd26.MOS1.HIV-Env 1x10^11 vp
Biological: rcAd26.MOS1.HIV-Env 1x10^8 vp

First Posted Date: 2015-02-19

Last Posted Date: 2016-11-21

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 22

Registration Number: NCT02366013

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy